TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: 20070360 Incident Dialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults greater than or equal to 18 years of age on hemodialysis for \> 3 and less than or equal to 12 months prior to enrollment into the study~* Mean of 2 PTH determinations during the screening period (drawn at least 2 days apart) \> 300 pg/mL (31.8 pmol/L); or biPTH \> 160 pg/mL (17.0 pmol/L)~* Mean of 2 corrected serum calcium determinations drawn on the same day as the PTH determinations greater than or equal to 8.4 mg/dL (2.1 mmol/L)~* Subject will be able to complete the study, to the best of his/her knowledge~* Before any study-specific procedure, the appropriate written informed consent must be obtained~Exclusion Criteria:~* Mean of 2 PTH determinations during the screening period (drawn at least 2 days apart) \> 800 pg/mL (84.9 pmol/L); or biPTH \> 430 pg/mL (45.6 pmol/L) AND receiving vitamin D on entering screening~* Parathyroidectomy (partial or full) less than or equal to 6 months before entering screening~* Anticipated parathyroidectomy (partial or full) within 6 months after randomization~* Have a scheduled date for kidney transplant surgery~* Received cinacalcet since initiating hemodialysis~* Have received vitamin D therapy for less than 30 days before entering screening or required a change in prescribed vitamin D brand or dose within 30 days before entering screening. If subjects are not receiving vitamin D therapy, they must remain free of vitamin D therapy for the 30 days before entering screening~* Subject is pregnant (eg, positive HCG test) or is breast-feeding~* Refusal to use highly effective contraceptive measures (as determined by the investigator) throughout the study (screening and post enrollment)~* Current gastrointestinal disorder that may be associated with impaired absorption of orally administered medications or an inability to swallow tablets~* Known sensitivity, intolerance, or other adverse response to cinacalcet which would prevent on-study treatment compliance~* Have an unstable medical condition within 30 days before screening, or otherwise unstable in the judgment of the investigator~* Subject is currently enrolled in, or fewer than 30 days prior to entering screening have passed since subject received other investigational agent(s) (devices or drug).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cinacalcet Group (Type: EXPERIMENTAL): Cinacalcet plus low dose active Vitamin D (if prescribed)
- Control Group (Type: ACTIVE_COMPARATOR): Flexible active vitamin D dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Plus Surgery in Treating Women With Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Unilateral carcinoma of the breast that has not been previously treated with standard therapies~* Tumor greater than 2 cm in its maximum diameter as assessed by mammography, except:~  * No locally advanced disease, i.e., no tumor with direct extension to the chest wall or skin~ * No metastatic disease~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 18 to 70~Sex:~* Female~Menopausal status:~* Not specified~Performance status:~* Karnofsky 80-100%~Hematopoietic:~* Granulocyte count at least 2,000/mm\^3~* Platelet count at least 150,000/mm\^3~Hepatic:~* Bilirubin within upper limits of normal (ULN)~* Alkaline phosphatase no greater than 1.5 times ULN~* AST no greater than 1.5 times ULN~* No chronic active hepatitis~Renal:~* Creatinine within ULN~Cardiovascular:~* No prior atrial or ventricular arrhythmias~* No history of congestive heart failure~* No myocardial infarction within the past 6 months~* No uncontrolled hypertension~Neurologic:~* No pre-existing motor or sensory neuropathy greater than grade 1~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No active infection~* No history of second malignancy except adequately treated basal cell skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior biologic therapy~Chemotherapy:~* No prior chemotherapy~Endocrine therapy:~* No prior endocrine therapy~Radiotherapy:~* No prior radiotherapy~Surgery:~* No prior surgery~* No prior surgical biopsy of breast nodule

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 or older at time of study entry~2. Willing and able to give informed consent~3. Diagnosed with CML in chronic phase and have either the b3a2 (e14a2) or b2a2 (e13a2) variants that give rise to the p210 BCR-ABL protein~4. Currently taking imatinib, dasatinib, nilotinib or bosutinib~5. Patient has been on TKI therapy for at least 3 years~6. Documented BCR-ABL \<0.01% (\>MR4 i.e. \>4 log reduction) or undetectable BCR-ABL by PCR for at least 2 years according to the patient's local lab~7. Documented BCR-ABL \<0.01% (\>MR4 i.e. \>4 log reduction) or undetectable BCR-ABL at least 3 times prior to screening according to the patient's local lab~8. Two (2) Screening PCRs have been completed and both results are \< 0.01% (\>MR4 i.e \> 4 log reduction) by central lab~9. Has been on any number of TKIs, but has not been resistant to any TKI (changes made for intolerance are allowed)~10. Patient has been compliant with therapy per treating physician~Exclusion Criteria:~1. Prior hematopoietic stem cell transplantation~2. Poor compliance with taking TKI~3. Unable to comply with lab appointments schedule and PRO assessments~4. Life expectancy less than 36 months~5. Patients who have been resistant to previous TKI therapy are not eligible~6. Pregnant or lactating women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Discontinuation of TKI medication (Type: OTHER): Patients with CML on treatment with imatinib, dasatinib, nilotinib, or bosutinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (\> 4 log reduction) molecular response (\>MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) \< 0.01%, for at least two years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Symptomatic Treatment Of Patients With Neuropathic Pain With LYRICA

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of neuropathic pain and inclusion according to the current Summary of Product Characteristics.~Exclusion Criteria:~* The patients were excluded according to the current Summary of Product Characteristics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with neuropathic pain (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preemptive Analgesia in Cruciate Reconstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with anterior cruciate ligament injury age 15-50 yr~Exclusion Criteria:~* previous knee surgery

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: EXPERIMENTAL): identical placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Infertility in Women With Polycystic Ovary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Eight or fewer menstrual cycles in the past year or intermenstrual periods of 45 days or longer~* Elevated testosterone level~* Good general health~* Sperm concentration in partner of 20 million/ml or greater~* Ability to have intercourse 2-3 times per week~* One functional fallopian tube and normal uterine cavity

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Transplant Medication Safety Through A Technology and Pharmacist Intervention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Veteran organ transplant recipients will be identified using International Classification of Diseases (ICD) 9/10 codes from the VA electronic health record (CPRS).~* Patients must have an active code stating they are a recipient of an organ transplant.~* The following codes will be utilized - ICD-9 codes:~  * V42.0~ * V42.1~ * V42.6~ * V42.7~ * V42.83~ * V42.84~ * 996.81~ * 996.82~ * 996.83~ * 996.84~ * 996.86~ * 52.80~OR~* oICD-10 codes:~  * C80.2~ * T86.1~ * T86.10~ * T86.11~ * T86.12~ * T86.13~ * T86.19~ * T86.2~ * T86.20~ * T86.21~ * T86.22~ * T86.23~ * T86.290~ * T86.298~ * T86.3~ * T86.30~ * T86.31~ * T86.32~ * T86.33~ * T86.39~ * T86.4~ * T86.40~ * T86.41~ * T86.42~ * T86.43~ * T86.49~ * T86.810~ * T86.811~ * T86.812~ * T86.818~ * T86.819~ * T86.9~ * Z48.2~ * Z48.21~ * Z48.22~ * Z48.23~ * Z48.24~ * Z48.280~ * Z48.288~ * Z48.298~ * Z94.0~ * Z94.1~ * Z94.2~ * Z94.3~ * Z94.4~ * Z94.83~AND~* Actively receiving at least one anti-rejection medication dispensed by the VA site.~* These medications include:~  * tacrolimus~ * cyclosporine~ * azathioprine~ * mycophenolate~ * sirolimus~ * everolimus~ * belatacept~Exclusion Criteria:~* There are no exclusion criteria for patients in this study as recruitment is at the level of the VA site.~* All veterans meeting inclusion criteria will be monitored by the dashboard system and will be included in the outcomes assessment.~* Patients may enter or exit the study in a rolling manner, which will be accounted for during analyses.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control Arm (Type: NO_INTERVENTION): Usual Care
- Intervention Arm (Type: EXPERIMENTAL): Technology-enabled pharmacist intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Currently on a stable antiretroviral regimen for ≥ 6 consecutive months~* Plasma HIV-1 ribonucleic acid (RNA) concentrations \< 50 copies/mL for ≥ 6 months preceding the screening visit and have HIV-1 RNA \< 50 copies/mL at screening~* No documented history of HIV-1 resistance to elvitegravir (EVG), emtricitabine (FTC), lamivudine (3TC) or tenofovir (TFV) and no history of switching off EVG, FTC, 3TC or TFV due to concern for resistance~* Cluster determinant 4 (CD4+) T cell count ≥ 200 cells/μL~* ESRD with estimated glomerular filtration rate (eGFR) \< 15 mL/min by Cockcroft-Gault formula for creatinine clearance~* On chronic HD for ≥ 6 months prior to screening~* Adequate hematologic function (absolute neutrophil count ≥ 1,000/mm\^3; platelets ≥ 50,000/mm\^3; hemoglobin ≥ 8.5 g/dL)~Key Exclusion Criteria:~* Hepatitis B co-infection~* Any clinical history, condition, or test result that, in the opinion of the Investigator, would make the individual unsuitable for the study or unable to comply with dosing requirements~* Administration of other investigational agents (unless approved by Gilead Sciences). Participation in any other clinical trial, including observational trials, without prior approval from the sponsor is prohibited while participating in this trial.~* History or presence of allergy or intolerance to the study drugs or their components~* A new acquired immunodeficiency syndrome (AIDS)-defining condition (excluding CD4+ T cell count and percentage criteria) diagnosed within the 30 days prior to screening, with the exception of oropharyngeal candidiasis~* Received solid organ or bone marrow transplant~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- E/C/F/TAF (Type: EXPERIMENTAL): Participants will switch their current antiretroviral regimen to E/C/F/TAF and receive treatment for 96 weeks. After Week 96, participants in the United States (US) who wish to participate in the open-label (OL) rollover extension will continue to take E/C/F/TAF FDC until the End of E/C/F/TAF Visit.
- Open-Label Rollover Extension B/F/TAF (Type: EXPERIMENTAL): At Week 96 or the End of E/C/F/TAF Visit (whichever occurs last), participants will be given the option to receive open-label bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for at least 48 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinically healthy subjects aged 18 years and above.~2. Subjects have been informed properly regarding the study and signed the informed consent form.~3. Subjects will commit to comply with the instructions of the investigator and the schedule of the trial.~Exclusion Criteria:~1. Subjects concomitantly enrolled or scheduled to be enrolled in another trial.~2. History of vaccination with any COVID-19 vaccine.~3. History of COVID-19 within 1 month (for mild-moderate disease) or 3 months (for severe disease) prior to enrollment.~4. Evolving mild, moderate, or severe illness, especially infectious disease, or fever (body temperature ≥37.5℃, measured with infrared thermometer/thermal gun).~5. Women who are pregnant or planning to become pregnant during the study period (judged by self-report of subjects and urine pregnancy test results).~6. History of uncontrolled asthma, allergy to vaccines or vaccine ingredients, and severe adverse reactions to vaccines, such as urticaria, dyspnea, and angioneurotic edema.~7. History of blood disorders contraindicating intramuscular injection.~8. Patients with serious chronic diseases (serious cardiovascular diseases, uncontrolled hypertension and diabetes, liver and kidney diseases, malignant tumors, etc.) which according to the investigator might interfere with the assessment of the trial objectives.~9. History of confirmed or suspected immunosuppressive or immunodeficient state or in the previous 4 weeks received a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products, or long-term corticosteroid therapy (\> 2 weeks)).~10. History of uncontrolled epilepsy or other progressive neurological disorders, such as Guillain-Barre Syndrome.~11. Subjects receive any vaccination (other than COVID-19 vaccine) within 1 month before and after IP immunization.~12. Subjects plan to move from the study area before the end of study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- COVID-19 Protein Subunit Recombinant Vaccine (Type: EXPERIMENTAL): 2 doses of COVID-19 Protein Subunit Recombinant Vaccine administered with 28 days interval (0.5 mL per dose)
- Active Comparator (Type: ACTIVE_COMPARATOR): 2 doses of Covovax® - recombinant spike protein Nanoparticle Vaccine, administered with 28 days interval (0.5 mL per dose)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Passive Ultrasonic Irrigation on the Reduction of Bacteria and Endotoxins in Root Canals

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Teeth with necrotic pulps and asymptomatic apical periodontitis~Exclusion Criteria:~* patients who had received antibiotics during the previous 3 months or had any general disease,~* teeth that could not be properly isolated with rubber dam,~* non-restored teeth,~* periodontal pockets depths greater than 4 mm,~* previous endodontic treatment,~* open apex,~* crown/root fracture~* root resorption or calcifications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Passive Ultrasonic Irrigation Protocol (Type: EXPERIMENTAL): ultrasonic activation of antimicrobial solutions
- Non-Ultrasonic Irrigation Protocol (Type: ACTIVE_COMPARATOR): no-activation of antimicrobial solutions

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sedating Antidepressant Improves Driving Safety in Patients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Fulfilling DSM-IV criteria for Major Depressive Disorder~* Score of Hamilton Rating Scale for Depression (HDRS-17) \> 17~* Patient to be prescribed mirtazapine (Remeron) as determined by physician~* Subject has no known clinically significant abnormal vital signs or other clinical findings at screening.~* Patients should have a driving license for more than 3 years and drive over 15,000 km year.~* Females of childbearing potential must willingly use effective birth control.~Exclusion Criteria:~* Night shift workers.~* A history or present condition of: Bipolar Disorder or Depressive Disorder not Otherwise Specified,Schizophrenia or other psychotic disorders (according to DSM-IV), Schizotypal or Borderline personality disorder, Organic mental disorders~* A present condition of: Anxiety Disorders (according to DSM-IV), Eating Disorders, Postpartum Depression~* Epilepsy or a history of seizure disorder or ever received treatment with anticonvulsant medication for epilepsy or seizures~* PSG recording of an extremely abnormal sleep EEG (other than that which would be expected with depression)~* Alcohol or substance abuse (according to DSM-IV) during the last 6months prior to baseline.~* Any physical disease, which may explain the symptoms of depression.~* Any chronic physical disease, which is not stabilized.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound-Monitored Changes in Achilles Tendinopathy After Extracorporeal Shock Wave Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* the patient complains about Achilles tendon pain, which limits (at least partially) his quality of life during daily activities or sport, and this condition would be referred as a tendinopathy~* the patient's other leg is asymptomatic~* the patient is not aware of the symptomatical mechanical tendon damage in past (eg. partial or complete rupture due to injury)~* the patient has no previous experience with extracorporeal shockwave therapy treatment~Exclusion Criteria:~* the patient has condition which is contraindication for extracorporeal shock wave therapy treatment~* the patient had symptomatical mechanical tendon damage in past (eg. partial or complete rupture due to injury)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Group (A) (Type: EXPERIMENTAL): Group of patients with Achilles tendinopathy which are treated by focused extracorporeal shockwave therapy once a week for 5 weeks. ESWT parameters: 0,12 mJ/mm2, 10 Hz, 1300 shocks.
- Sham Group (B) (Type: SHAM_COMPARATOR): Group of patients with Achilles tendinopathy in which sham extracorporeal shockwave therapy is applied once a week for 5 weeks. Total applications are 5, applicated weekly. Sham ESWT parameters are same as in Group A (0,12 mJ/mm2, 10 Hz, 1300 shocks) but with modified applicator which does not allow wave transmission.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete